PHA-543613 acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good orally bioavailable bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia. References: Sadigh-Eteghad S, Mahmoudi J, Babri S, Talebi M. Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function. Acta Cir Bras. 2015 Nov;30(11):736-42. doi: 10.1590/S0102-865020150110000003. PubMed PMID: 26647792.

纯度：≥98%

CAS：478149-53-0